Global Rivaroxaban 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR012503396

Publication Date:

January 10, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Rivaroxaban market size was valued at US$ 8958 million in 2024 and is forecast to a readjusted size of USD 15270 million by 2031 with a CAGR of 8.0% during review period.
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8鈥�12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
This report is a detailed and comprehensive analysis for global Rivaroxaban market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Rivaroxaban market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Rivaroxaban market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Rivaroxaban market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Rivaroxaban market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Rivaroxaban
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Rivaroxaban market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, J&J, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Rivaroxaban market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
2.5 mg
10 mg
15 mg
20 mg
麻豆原创 segment by Application
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
Major players covered
Bayer
J&J
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Rivaroxaban product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Rivaroxaban, with price, sales quantity, revenue, and global market share of Rivaroxaban from 2020 to 2025.
Chapter 3, the Rivaroxaban competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Rivaroxaban breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Rivaroxaban market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Rivaroxaban.
Chapter 14 and 15, to describe Rivaroxaban sales channel, distributors, customers, research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Rivaroxaban Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 2.5 mg
1.3.3 10 mg
1.3.4 15 mg
1.3.5 20 mg
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Rivaroxaban Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Acute Coronary Syndrome (ACS)
1.4.3 Venous Thromboembolism (VTE)
1.5 Global Rivaroxaban 麻豆原创 Size & Forecast
1.5.1 Global Rivaroxaban Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Rivaroxaban Sales Quantity (2020-2031)
1.5.3 Global Rivaroxaban Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Rivaroxaban Product and Services
2.1.4 Bayer Rivaroxaban Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Bayer Recent Developments/Updates
2.2 J&J
2.2.1 J&J Details
2.2.2 J&J Major Business
2.2.3 J&J Rivaroxaban Product and Services
2.2.4 J&J Rivaroxaban Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 J&J Recent Developments/Updates
3 Competitive Environment: Rivaroxaban by Manufacturer
3.1 Global Rivaroxaban Sales Quantity by Manufacturer (2020-2025)
3.2 Global Rivaroxaban Revenue by Manufacturer (2020-2025)
3.3 Global Rivaroxaban Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Rivaroxaban by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Rivaroxaban Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Rivaroxaban Manufacturer 麻豆原创 Share in 2024
3.5 Rivaroxaban 麻豆原创: Overall Company Footprint Analysis
3.5.1 Rivaroxaban 麻豆原创: Region Footprint
3.5.2 Rivaroxaban 麻豆原创: Company Product Type Footprint
3.5.3 Rivaroxaban 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Rivaroxaban 麻豆原创 Size by Region
4.1.1 Global Rivaroxaban Sales Quantity by Region (2020-2031)
4.1.2 Global Rivaroxaban Consumption Value by Region (2020-2031)
4.1.3 Global Rivaroxaban Average Price by Region (2020-2031)
4.2 North America Rivaroxaban Consumption Value (2020-2031)
4.3 Europe Rivaroxaban Consumption Value (2020-2031)
4.4 Asia-Pacific Rivaroxaban Consumption Value (2020-2031)
4.5 South America Rivaroxaban Consumption Value (2020-2031)
4.6 Middle East & Africa Rivaroxaban Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Rivaroxaban Sales Quantity by Type (2020-2031)
5.2 Global Rivaroxaban Consumption Value by Type (2020-2031)
5.3 Global Rivaroxaban Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Rivaroxaban Sales Quantity by Application (2020-2031)
6.2 Global Rivaroxaban Consumption Value by Application (2020-2031)
6.3 Global Rivaroxaban Average Price by Application (2020-2031)
7 North America
7.1 North America Rivaroxaban Sales Quantity by Type (2020-2031)
7.2 North America Rivaroxaban Sales Quantity by Application (2020-2031)
7.3 North America Rivaroxaban 麻豆原创 Size by Country
7.3.1 North America Rivaroxaban Sales Quantity by Country (2020-2031)
7.3.2 North America Rivaroxaban Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Rivaroxaban Sales Quantity by Type (2020-2031)
8.2 Europe Rivaroxaban Sales Quantity by Application (2020-2031)
8.3 Europe Rivaroxaban 麻豆原创 Size by Country
8.3.1 Europe Rivaroxaban Sales Quantity by Country (2020-2031)
8.3.2 Europe Rivaroxaban Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Rivaroxaban Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Rivaroxaban Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Rivaroxaban 麻豆原创 Size by Region
9.3.1 Asia-Pacific Rivaroxaban Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Rivaroxaban Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Rivaroxaban Sales Quantity by Type (2020-2031)
10.2 South America Rivaroxaban Sales Quantity by Application (2020-2031)
10.3 South America Rivaroxaban 麻豆原创 Size by Country
10.3.1 South America Rivaroxaban Sales Quantity by Country (2020-2031)
10.3.2 South America Rivaroxaban Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Rivaroxaban Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Rivaroxaban Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Rivaroxaban 麻豆原创 Size by Country
11.3.1 Middle East & Africa Rivaroxaban Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Rivaroxaban Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Rivaroxaban 麻豆原创 Drivers
12.2 Rivaroxaban 麻豆原创 Restraints
12.3 Rivaroxaban Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Rivaroxaban and Key Manufacturers
13.2 Manufacturing Costs Percentage of Rivaroxaban
13.3 Rivaroxaban Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Rivaroxaban Typical Distributors
14.3 Rivaroxaban Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Companies Mentioned:

Bayer
J&J

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.